The proposed research program is directed at studying the specific role of the X chromosome in cancer progression and at creating a Molecular Pathology research facility that will be used to identify new X chromosome-related targets for cancer therapy, and to validate them in a large cohort of tumour samples. This will be developed primarily in a variant of breast cancers that is refractory to current therapies and in cutaneous melanomas. The results will be tested in other forms of cancers, especially in prostate and colon cancers. It is expected that the establishment of this infrastructure will lead to new treatments of cancer and faster processes for biomarkers validation.